Acurx Pharmaceuticals, Inc. Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired
Acurx Pharmaceuticals, Inc. (ACXP) reported Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired of $2.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired · last filed 2026-03-12
- Acurx Pharmaceuticals, Inc. research and development asset acquired other than through business combination, fair value acquired for fiscal 2025 was $2.20M, a 61.40% decline from fiscal 2024.
- Acurx Pharmaceuticals, Inc. research and development asset acquired other than through business combination, fair value acquired for fiscal 2024 was $5.70M, a 6.56% decline from fiscal 2023.
- Acurx Pharmaceuticals, Inc. research and development asset acquired other than through business combination, fair value acquired for fiscal 2023 was $6.10M, a 27.08% increase from fiscal 2022.
- Acurx Pharmaceuticals, Inc. research and development asset acquired other than through business combination, fair value acquired for fiscal 2022 was $4.80M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 12 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.20M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $5.70M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $6.10M 10-K · filed 2025-03-17 | |
| 2022-12-31 | $4.80M 10-K · filed 2024-03-15 | $4.30M 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |